Maria Andreea Catana, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory-Gated Imaging Techniques | 1 | 2018 | 75 | 0.580 |
Why?
|
| Abdominal Neoplasms | 1 | 2018 | 287 | 0.540 |
Why?
|
| Liver Transplantation | 4 | 2020 | 2332 | 0.430 |
Why?
|
| Abdomen | 2 | 2018 | 1128 | 0.430 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 4309 | 0.350 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2021 | 172 | 0.320 |
Why?
|
| Liver Diseases | 4 | 2023 | 1301 | 0.280 |
Why?
|
| Liver Cirrhosis | 4 | 2020 | 1932 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 2293 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 1 | 2006 | 401 | 0.220 |
Why?
|
| Yttrium Radioisotopes | 1 | 2024 | 107 | 0.210 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 6585 | 0.190 |
Why?
|
| Microspheres | 1 | 2024 | 783 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2020 | 156 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 368 | 0.140 |
Why?
|
| Hepatocytes | 3 | 2008 | 1231 | 0.120 |
Why?
|
| Motion | 1 | 2018 | 779 | 0.120 |
Why?
|
| Superoxide Dismutase | 2 | 2007 | 593 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.110 |
Why?
|
| Minority Groups | 1 | 2020 | 1201 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36415 | 0.090 |
Why?
|
| Fetal Stem Cells | 1 | 2008 | 10 | 0.080 |
Why?
|
| Lentivirus | 2 | 2008 | 508 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2015 | 1395 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3744 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7804 | 0.070 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 340 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2015 | 1579 | 0.060 |
Why?
|
| Thymoma | 1 | 2006 | 188 | 0.060 |
Why?
|
| Thoracic Neoplasms | 1 | 2006 | 268 | 0.060 |
Why?
|
| Middle Aged | 12 | 2024 | 220853 | 0.060 |
Why?
|
| Male | 14 | 2024 | 360693 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2007 | 1201 | 0.050 |
Why?
|
| Extracellular Fluid | 1 | 2004 | 165 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2015 | 3239 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2004 | 472 | 0.050 |
Why?
|
| Hospitalization | 4 | 2023 | 10707 | 0.050 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2006 | 492 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 110 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 1246 | 0.040 |
Why?
|
| Female | 12 | 2024 | 392544 | 0.040 |
Why?
|
| Adult | 8 | 2023 | 221119 | 0.040 |
Why?
|
| Humans | 19 | 2024 | 761208 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 1600 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 525 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 602 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1668 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15841 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2007 | 3114 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 352 | 0.030 |
Why?
|
| Aged | 7 | 2024 | 169288 | 0.030 |
Why?
|
| Creatinine | 1 | 2020 | 1897 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 29687 | 0.030 |
Why?
|
| Registries | 2 | 2020 | 8247 | 0.030 |
Why?
|
| Europe | 1 | 2021 | 3423 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2020 | 41496 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1916 | 0.030 |
Why?
|
| Albumins | 2 | 2008 | 575 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2007 | 11509 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2008 | 2621 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20588 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2024 | 80674 | 0.020 |
Why?
|
| Culture Media | 2 | 2004 | 894 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 58952 | 0.020 |
Why?
|
| Stem Cells | 1 | 2004 | 3517 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2020 | 9319 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2631 | 0.020 |
Why?
|
| Risk Factors | 3 | 2020 | 74239 | 0.020 |
Why?
|
| Mortality | 1 | 2020 | 2896 | 0.020 |
Why?
|
| Transfection | 2 | 2008 | 5748 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2008 | 37 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 10088 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2008 | 167 | 0.020 |
Why?
|
| Graft Survival | 2 | 2008 | 3843 | 0.020 |
Why?
|
| Transferrin | 1 | 2008 | 283 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 864 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13249 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2007 | 16952 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10516 | 0.020 |
Why?
|
| Carcinogens | 1 | 2008 | 452 | 0.020 |
Why?
|
| Acute Disease | 2 | 2007 | 7226 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 59221 | 0.010 |
Why?
|
| Transgenes | 1 | 2007 | 1008 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2008 | 1518 | 0.010 |
Why?
|
| Cations | 1 | 2004 | 238 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13511 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2004 | 271 | 0.010 |
Why?
|
| Superoxides | 1 | 2004 | 388 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2007 | 1822 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 88298 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5493 | 0.010 |
Why?
|
| Mice | 5 | 2008 | 81326 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 2062 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 581 | 0.010 |
Why?
|
| Spleen | 1 | 2008 | 2290 | 0.010 |
Why?
|
| Urea | 1 | 2004 | 442 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11119 | 0.010 |
Why?
|
| Liposomes | 1 | 2004 | 783 | 0.010 |
Why?
|
| United States | 2 | 2020 | 72339 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 2406 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 2261 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 24021 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 3388 | 0.010 |
Why?
|
| Ethanol | 1 | 2004 | 1322 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 5778 | 0.010 |
Why?
|
| Animals | 5 | 2008 | 168079 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2024 | 64681 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 2199 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2004 | 1945 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3596 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 5032 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 1662 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2902 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 2548 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15545 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 3331 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 18926 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 11067 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 22127 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 6588 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 7514 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 18220 | 0.000 |
Why?
|
| Models, Biological | 1 | 2004 | 9457 | 0.000 |
Why?
|
| Time Factors | 1 | 2004 | 39957 | 0.000 |
Why?
|